Spesolimab. Anti-IL-36R monoclonal antibody Treatment of generalized pustular psoriasis Treatment of immune-mediated inflammatory diseases
Research output: Contribution to journal › Journal article › Research › peer-review
The palette of biologic therapy is growing rapidly to improve the treatment and management of inflammatory immune-driven diseases. The interleukin-36 (IL-36) receptor has become a prom-ising target for therapeutic intervention, with early studies of anti-IL-36 receptor treatment demonstrating rapid inhibition of the IL-36 signaling pathway and improvement of disease symp-toms. Spesolimab, a humanized anti-IL-36 receptor monoclo-nal antibody, is one of the latest additions, showing promising results in the treatment of generalized pustular psoriasis and a possible effect in ulcerative colitis. In this review, we present the current literature on spesolimab, including pharmacodynam-ics, pharmacokinetics, efficacy and safety in the treatment of several immune-mediated inflammatory diseases.
Original language | English |
---|---|
Journal | Drugs of the Future |
Volume | 48 |
Issue number | 3 |
Pages (from-to) | 165-172 |
ISSN | 0377-8282 |
DOIs | |
Publication status | Published - 2023 |
- Spesolimab, BI-655130, MAB-92, Generalized pustular psoriasis, IL-36R, Monoclonal antibody
Research areas
ID: 340531009